Bayer issues a guidance on Trasylol, stating that it should only be used as directed on its label.
Bayer's Trasylol (aprotinin injection) can reduce bleeding in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. However, a new study has found that patients on the treatment also had a higher death rate than patients who received either aminocaproic acid or tranexamic acid. For this reason, Bayer has halted the trial and issued a new guidance to health professionals. The guidance states that Trasylol should be used only according to its labeling. More information can be found on
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
Assessing Financial Impacts of Pharmacist-Led Interventions in Pediatric Ambulatory Care
December 5th 2023According to a poster abstract presented at the ASHP Midyear Clinical Meeting & Exhibition, specialty pharmacy services were used for a variety of conditions that have been reported in adult populations.